Foghorn Therapeutics Inc. filings document a clinical-stage biotechnology issuer with common stock listed on the Nasdaq Global Market under FHTX. The company’s current-event filings cover financial results, Regulation FD investor presentations, oncology pipeline disclosures for FHD-909 and selective CBP, EP300 and ARID1B degrader programs, and collaboration-related revenue.
Proxy and 8-K filings also address annual-meeting voting matters, board and executive governance, officer appointments, compensatory arrangements, material agreements, capital-structure disclosures and security-registration details tied to the company’s common stock and financing activity.
Foghorn Therapeutics is holding a virtual-only 2026 annual stockholder meeting on June 24, 2026, with April 27, 2026 as the record date and 58,713,922 common shares entitled to vote. Stockholders will vote on electing three Class III directors, ratifying Deloitte & Touche LLP as auditor, an advisory say-on-pay, and say-on-frequency (the Board recommends one year).
The proxy details a classified three-class Board, committee composition, director independence, and an updated non-employee director compensation policy with higher cash retainers and larger option grants. It reports significant holders, including Flagship Pioneering funds at 27.14% and Biotechnology Value Fund affiliates at 10.33%, and shows all directors and officers collectively owning 9.02% as of April 20, 2026.
Named executive officer pay is outlined: in 2025 CEO Adrian Gottschalk received $2.36 million in total compensation, including $638,000 salary, $385,990 bonus and $1.33 million in option awards, with similar stock-based packages for the Chief Scientific and Chief Medical Officers. The filing explains severance and change-in-control protections, a Dodd-Frank-compliant clawback policy, and an insider trading policy.
The proxy includes “pay versus performance” disclosure showing net losses of $74.3 million in 2025 and $86.6 million in 2024 and total shareholder return values of 83.72 and 73.18, respectively, on a hypothetical $100 investment. Deloitte’s audit fees totaled $877,827 in 2025. Related-party sections describe a consulting agreement with founder Cigall Kadoch, Ph.D., a collaboration and equity position with Eli Lilly, and a January 2026 $50 million equity financing with major existing investors.
Foghorn Therapeutics Inc. filed an 8-K describing new preclinical data and an updated investor presentation focused on its chromatin biology pipeline. The company highlighted FHD-909, a selective SMARCA2 inhibitor partnered with Lilly, which in mouse models produced complete and durable tumor regression and apparent anti-tumor immune memory when combined with an anti-PD-1 antibody.
Foghorn also reported strong preclinical activity for its selective CBP degrader FHT-171 in heavily pretreated ER+ breast cancer models, and selective EP300 degraders that outperformed dual CBP/EP300 inhibitor inobrodib in multiple myeloma models while sparing platelets. Cereblon-based selective ARID1B degraders showed robust target degradation and transcriptional effects in ARID1A‑mutant cancer settings. The company notes a major collaboration with Lilly and states it had $158.9 million in cash and equivalents as of December 31, 2025, plus $50 million of gross proceeds from a January 2026 financing, supporting a cash runway into the first half of 2028.
Foghorn Therapeutics Inc. Chief Executive Officer Adrian Gottschalk reported a series of bona fide gifts of Common Stock between family estate-planning vehicles. On April 9 and 10, 2026, four indirect transactions moved a total of 213,410 shares among grantor retained annuity trusts and his Living Trust at a stated price of $0.00 per share.
The 2023 Grantor Retained Annuity Trust distributed 47,497 shares to the Adrian H. Gottschalk Living Trust, leaving the 2023 GRAT with 0 shares and the Living Trust with 211,704 shares indirectly held. Separately, the 2025 Grantor Retained Annuity Trust distributed 59,208 shares to the Living Trust, after which the 2025 GRAT held 240,792 shares and the Living Trust held 270,912 shares, all reported as indirect ownership. These movements are characterized as gift transfers rather than open-market trades.
Foghorn Therapeutics is a clinical-stage biotechnology company developing precision medicines that correct abnormal gene expression by targeting the chromatin regulatory system, which is implicated in roughly half of all cancers. Its proprietary Gene Traffic Control® platform combines genomics, epigenomics, AI tools and protein degradation technologies to identify genetically driven dependencies and drug them selectively.
The lead program, FHD-909, is a first-in-class oral SMARCA2-selective inhibitor being developed with Eli Lilly for SMARCA4-mutated cancers, particularly non-small cell lung cancer, with a Phase 1 trial underway after first dosing in October 2024. Foghorn and Lilly are also advancing a SMARCA2 degrader and additional oncology discovery programs.
The pipeline includes selective degraders of CBP, EP300 and ARID1B aimed at tumor types where paralog mutations create synthetic lethal vulnerabilities across solid tumors and hematologic cancers. Management believes the current portfolio could benefit more than 500,000 cancer patients and supports the potential to file four INDs over the next two years. As of December 31, 2025, the company had 106 employees and remains pre-commercial with no approved products, highlighting typical biotechnology risks such as ongoing losses, funding needs, clinical uncertainty and strong competition.
Foghorn Therapeutics reported 2025 results and outlined its oncology pipeline progress and financing. Collaboration revenue rose to $30.9 million from $22.6 million, while research and development expenses fell to $85.5 million from $94.5 million. General and administrative expenses edged down to $27.6 million from $28.4 million, and net loss improved to $74.3 million from $86.6 million, or $1.18 per share versus $1.58 in 2024.
As of December 31, 2025, Foghorn held $158.9 million in cash, cash equivalents and marketable securities. A $50 million registered direct financing completed in January 2026 at $6.71 per share, with warrants struck at $13.42 and $20.13, extends cash runway into the first half of 2028. The company highlighted its Phase 1 SMARCA2 inhibitor FHD‑909 partnered with Lilly, plus selective CBP, EP300 and ARID1B degrader programs tracking toward IND‑enabling work in 2026.
Foghorn Therapeutics Inc. reported that Chief Financial Officer Ryan D. Maynard was granted a stock option to acquire 400,000 shares of common stock at an exercise price of $5.75 per share. The option vests 25% on February 23, 2027, then 6.25% quarterly until fully vested.
Foghorn Therapeutics Inc. filed a Form 3 for Chief Financial Officer Maynard Ryan D, providing his initial statement of beneficial ownership in the company’s stock. The filing does not list any specific share transactions, focusing instead on establishing his reporting status as an executive officer.
Foghorn Therapeutics Inc. appointed Ryan D. Maynard as Chief Financial Officer, effective February 23, 2026. He will serve as the company’s principal financial and accounting officer, succeeding interim CFO Jeff Sacher.
Maynard brings more than 25 years of executive finance experience at biopharmaceutical and healthcare companies, including prior CFO roles at Cara Therapeutics, LetsGetChecked, Blade Therapeutics, and Rigel Pharmaceuticals. His employment terms include a $510,000 annual base salary, eligibility for an annual performance bonus targeted at 40% of base salary, a $90,000 signing bonus, and a stock option to purchase 400,000 Foghorn common shares under the 2020 Equity Incentive Plan. The option vests 25% on the first anniversary of grant and the remaining 75% in equal quarterly installments over the following 12 quarters, subject to continued employment.
The company issued a press release highlighting Maynard’s track record in capital markets, strategic transactions, and commercial planning, as well as his ongoing board role at Iovance Biotherapeutics. Foghorn reiterated its focus on developing oncology medicines targeting the chromatin regulatory system and referenced forward-looking statements about its pipeline, clinical trials, and cash runway.
Foghorn Therapeutics Inc. Chief Executive Officer and director Adrian Gottschalk received a new stock option grant. On February 5, 2026, he was awarded an option to purchase 1,075,000 shares of Foghorn Therapeutics common stock at an exercise price of $5.23 per share.
The option vests as to 25% of the underlying shares on February 5, 2027, then 6.25% of the shares vest on the first day of each calendar quarter thereafter. Following this grant, Gottschalk beneficially owns 1,075,000 derivative securities directly.